Department of Pharmacy, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.
Department of Pharmacology, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain.
Eur J Hosp Pharm. 2020 Jan;27(1):52-54. doi: 10.1136/ejhpharm-2018-001752. Epub 2018 Dec 1.
Thiscase report concerns a 34-year-old male with a hip prosthesis infection, under treatment with antidepressant and antihypertensive drugs, who presented with an increase in blood pressure after four days of treatment with oral tedizolid. Tedizolid was discontinued, and the dose of antihypertensive was increased. The patient progressively achieved the normalisation of blood pressure values, which allowed a reduction in the antihypertensive agent dose to its usual regimen. No cases of hypertension or serotonin toxicity are described in the initial tedizolid studies, where patients treated with other serotonergic drugs were excluded. However, this does not mean that these effects may not occur in clinical practice, especially in patients under concomitant treatment with this type of medication, because of the greater risk of drug interactions. The causality of this suspected drug reaction was analysed and it was considered as possible. The case has been reported to the pharmacovigilance system.
本病例报告涉及一名 34 岁男性,患有髋关节假体感染,正在服用抗抑郁药和降压药,在口服替地唑利治疗四天后血压升高。停用替地唑利,并增加降压药剂量。患者的血压值逐渐恢复正常,从而可以将降压药剂量减少至常规方案。在替地唑利的最初研究中,没有描述高血压或血清素毒性的病例,其中排除了接受其他血清素能药物治疗的患者。然而,这并不意味着这些影响在临床实践中不会发生,尤其是在同时接受此类药物治疗的患者中,因为药物相互作用的风险更大。对这种疑似药物反应的因果关系进行了分析,认为其可能性较大。该病例已向药物警戒系统报告。